A randomized, double-blind, placebo-controlled, five parallel group study investigating the efficacy and safety of BI 1356 BS (0.5 mg, 2.5 mg and 5.0 mg administered orally once daily) over 12 weeks in drug naïve and treated patients with Type 2 diabetes with insufficient glycemic control (study includes an open-label metformin treatment arm) Investigate the efficacy, safety and tolerability of several doses of BI 1356 BS ( 0.5 mg, 2.5 mg and 5.0 mg daily) compared to placebo over 12 weeks of treatment in patients with Type 2 diabetes and ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized, double-blind, placebo-controlled two-year trial to examine the changes in Exercise Endurance and COPD Patients Treated with Tiotropium (Spiriva (R) HandiHaler (R)) 18 µg once daily (EXACTT trial) Evaluate the effects on exercise duration of 96 weeks treatment with 18 mcg tiotropium (Spiriva HandiHaler) daily, in patients with COPD compared to placebo.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An open – label clinical trial to study pharmacokinetics (PK) of different levels (0.125 mg, 0,25 mg, 0.5 mg) of pramipexole taken once a day by month in children who can accepte stable pramipesole doses for the treatment of Restless Leg Syndrome (RLS) – A disorder which feel the urge to move the legs to reduce the unpleasant sensation The primary objective of the study was to assess the pharmacokinetics of PPX in pediatric RLS patients. The total and maximum exposure, absorption, distribution and elimination after multiple administ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase III, eight week randomised double-blind, double-dummy, forced titration study to compare the fixed-dose combination tablet of telmisartan 80 mg plus amlodipine 10 mg versus amlodipine 10 mg over encapsulated capsules mono-therapy as first line therapy in patients with type 2 diabetes mellitus and Stage I or II hypertension To demonstrate that the fixed-dose combination of telmisartan 80 mg plus amlodipine 10 mg is superior as first line therapy in reducing mean seated trough cuff systolic blood presure compared to the m...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

BI 10773 Cardiovascular outcome event trial in Type 2 Diabetes Mellitus patients The primary endpoint is time to the first occurrence of any of the following adjudicated components of the primary composite endpoint: CV death (including fatal stroke and fatal MI), non-fatal MI (exc...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized, double-blind, placebo- controlled, flexible dose study to evaluate the effectiveness and safety of pramipexole IR (0.125 – 0.5mg/day) compared to placebo for 6 weeks in children and adolescents (age 6-17 years) who are diagnosed with Tourette’s Disorder The primary objective of this trial is to evaluate the safety and efficacy of the non ergot dopamine agonist pramipexole for the treatment of tics in children and adolescents (age 6-17 years inclusive...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune